Autopsy report · NCT04591808

Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia

“for strategic reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 11 months before it started.
• Ran for about 7 months before it stopped.
• 146 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Institut de Recherches Internationales Servier

Sponsor type

University, hospital or other

Conditions

Dyslipidemias; Hypertension

Interventions

Atorvastatin/Perindopril; Atorvastatin; Perindopril

Participants

146

Sites

43

Countries

Georgia, Russia, Ukraine

Trials that died the same way

• Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects
  “Strategic Reasons” (90% match in meaning)
• Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
  “Due to strategic reasons” (84% match in meaning)
• Incisionless Treatment for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass
  “For business reasons” (82% match in meaning)
• S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
  “Strategic development reasons” (77% match in meaning)
• IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE
  “for strategic and pandemic reasons” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.